Entresto (sacubitril/valsartan) - Novartis, ROVI Pharmaceuticals Laboratories
Functional Mitral Regurgitation Trajectories in CRT-Treated HFrEF During Medical Therapy Optimization: Association with Reverse Remodeling. (PubMed, J Clin Med) - Oct 17, 2026 - "These findings describe parallel longitudinal changes in MR severity and cardiac structure within a combined device- and pharmacological-treatment setting. The observed changes cannot be disentangled from ongoing CRT-mediated remodeling, concomitant GDMT, changes in loading conditions, or other time-dependent factors and cannot be attributed specifically to sacubitril/valsartan." 
Journal • Cardiovascular • Heart Failure
http://www.ncbi.nlm.nih.gov/pubmed/42882149
 
Bogdan Enache; Constantin-Tudor Luca; Liviu Cirin; Maria-Laura Cr?ciun; Mirela Vîrtosu; Silvia Luca
 
Oct 17, 2026
 
Prev Next